POTOMAC, Md., July 22, 2021–(Organization WIRE)–India Globalization Funds, Inc. (the “Company”) (NYSE American: IGC) introduced right now that on July 20, 2021, the United States Patent and Trademark Office environment (“USPTO”) issued a patent (#11,065,225) for the therapy of Alzheimer’s illness entitled “Extremely-Small dose THC as a probable therapeutic and prophylactic agent for Alzheimer’s Sickness.”
The original patent application was initiated by the University of South Florida (“USF”) and filed on August 1, 2016. On May perhaps 25, 2017, IGC entered into an exclusive license arrangement with USF with respect to the patent software and the linked study done on Alzheimer’s disorder.
The granted patent relates to IGC’s proprietary formulation supposed to guide in the treatment method of persons living with Alzheimer’s disease. IGC’s proprietary formulation, IGC-Advertisement1, is the topic of the Company’s formerly-disclosed Phase 1 medical trial. The Organization just lately announced the completion of Cohort 3 in its placebo-managed Several Ascending Dose (MAD) stage 1 trial for establishing security and tolerability of IGC-Advert1 that uses THC on people suffering from Alzheimer’s sickness.
This press release has forward-looking statements within just the meaning of Area 21E of the Securities Trade Act of 1934. These forward-wanting statements are based mostly on IGC’s expectations and are subject to numerous dangers and uncertainties, selected of which are further than IGC’s management. Actual success could differ materially from these ahead-on the lookout statements as a result of, among other elements, the Company’s failure or lack of ability to commercialise one or extra of the Company’s solutions or technologies, including the investigational new drug or formulation described in this release, or failure to get Fda approval for the investigational new drug tests effects from human clinical trials that could not be favorable or as anticipated basic financial ailments that are significantly less favorable than envisioned, which include as a result of the ongoing COVID-19 pandemic the FDA’s basic situation concerning cannabis- and hemp-primarily based products and other things, many of which are reviewed in IGC’s SEC filings. IGC incorporates by reference the human demo disclosures and Risk Components determined in its Yearly Report on Variety 10-K submitted with the SEC on June 14, 2021, as if thoroughly integrated and restated herein. Looking at these pitfalls and uncertainties, there can be no assurance that the ahead-looking details contained in this release will manifest.
India Globalization Cash, Inc. (IGC) engages in the development of cannabinoid-based mostly therapies for indications such as Alzheimer’s ailment and suffering. It operates in two strains of business, Infrastructure and Lifestyle Sciences and is headquartered in Potomac, MD.
Look at supply version on businesswire.com: https://www.businesswire.com/information/home/20210722005361/en/
Claudia Grimaldi / 301-983-0998